medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-3-68-74medsovet-1753Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYОРЛИСТАТ В КОМПЛЕКСНОЙ ТЕРАПИИ ОЖИРЕНИЯ И САХАРНОГО ДИАБЕТА 2-го ТИПАORLISTAT IN COMBINATION THERAPY OF OBESITY AND TYPE 2 DIABETESМкртумянА. М.MkrtumyanA. M.

д.м.н., профессор

MD, Prof.

БирюковаЕ. В.BiryukovaE. V.

д.м.н., профессор

MD, Prof.

Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation201730122017036874Copyright © Мкртумян А.М., Бирюкова Е.В., 20172017Мкртумян А.М., Бирюкова Е.В.Mkrtumyan A.M., Biryukova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1753

В последние годы проблеме профилактики и лечения ожирения уделяется все больше внимания. Уже давно ожирение рассматривается не просто как избыток жировой ткани в организме, а как хроническое рецидивирующее заболевание, результат нарушения энергетического баланса, которое развивается при увеличении потребления пищи и снижении расхода энергии и тесно ассоциировано с рядом серьезных осложнений. В фармакотерапии ожирения широко применяется орлистат (Ксеникал)  – препарат периферического действия, не обладающий системными эффектами [11, 24, 27]. Ксеникал – это наиболее изученный фармакологический препарат для снижения веса. Свыше 30 000 пациентов с избыточным весом были вовлечены в КИ, из них – более 2 500 пациентов с СД2. Препарат и на сегодняшний день остается прорывом в лечении избыточного веса/ожирения.

Over the past years, the focus has been growing on the prevention and treatment of obesity. Obesity has long been considered not just as excess body fat but as a chronic relapsing disease, the result of energy disbalance, which develops with an increase in food intake and reduced energy expenditure and is closely associated with a number of serious complications. Orlistat (Xenical), a peripherally acting drug without systemic effects [11, 24, 27], has been widely used in pharmacological treatment of obesity. Xenical is the most well-studied medication for weight loss. More than 30,000 patients with obesity were involved in clinical trials, of which over 2,500 patients had type 2 diabetes. Till today, the drug remains a breakthrough in the treatment of overweight/obesity.

сахарный диабет 2-го типаожирениефармакотерапияорлистатtype 2 diabetesobesitypharmacotherapyorlistatReferencesМорбидное ожирение. Под ред. И.И. Дедова. М.: Медицинское информационное агентство, 2014.Морбидное ожирение. Под ред. И.И. Дедова. М.: Медицинское информационное агентство, 2014.Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med., 2007, 120(3 Suppl 1): S26-34.Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med., 2007, 120(3 Suppl 1): S26-34.Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res, 2002, 10(1): 14S-21S.Aronne LJ, Segal RK. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res, 2002, 10(1): 14S-21S.Björntorp P. Metabolic implications of body fat distribution. Diabetes Care, 1991, 14: 1132–1143.Björntorp P. Metabolic implications of body fat distribution. Diabetes Care, 1991, 14: 1132–1143.Btay GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999, 20: 805-75.Btay GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999, 20: 805-75.Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med., 2003, 348(17): 1625-1638.Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med., 2003, 348(17): 1625-1638.Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci, 2010, 1212: E1–E19.Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci, 2010, 1212: E1–E19.Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord, 1998, 22: 39-47.Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord, 1998, 22: 39-47.Galanis DJ, Harris T, Sharp D, Petrovich H. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol, 1998, 147: 379-86.Galanis DJ, Harris T, Sharp D, Petrovich H. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol, 1998, 147: 379-86.Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes. Diabetes Obes Metab, 2002, 4: 415-23.Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes. Diabetes Obes Metab, 2002, 4: 415-23.Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 2000, 20: 270-9.Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 2000, 20: 270-9.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444: 840–846.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444: 840–846.Pinkston MM, Poston WS, Reeves RS et al. Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord, 2006, 11(1): 35-41.Pinkston MM, Poston WS, Reeves RS et al. Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord, 2006, 11(1): 35-41.Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension, 2005, 45: 9-14.Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension. Hypertension, 2005, 45: 9-14.Richelsen B, Tonstad S, Rossner S et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care, 2007, 30(1): 27-32.Richelsen B, Tonstad S, Rossner S et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care, 2007, 30(1): 27-32.Rowe R, Cowx M, Poole C et al The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin, 2005, 21(11): 1885-90.Rowe R, Cowx M, Poole C et al The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin, 2005, 21(11): 1885-90.Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patient with. J. Hypertens., 2002, 29: 1873-8.Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patient with. J. Hypertens., 2002, 29: 1873-8.Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352: 167-72.Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352: 167-72.Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subjects (XENDOC) study, a randomized study of orlistat as an agjunct to lifestyle changes for the prevention of type 2 diabetes in obese patient. Diabetes Care, 2004, 27: 155-161.Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subjects (XENDOC) study, a randomized study of orlistat as an agjunct to lifestyle changes for the prevention of type 2 diabetes in obese patient. Diabetes Care, 2004, 27: 155-161.Tounian P, Aggoun Y, Dubern B et al: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet, 2001, 385: 1400-04.Tounian P, Aggoun Y, Dubern B et al: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet, 2001, 385: 1400-04.Tremblay A, Buemann B. Exercise-training, macronutrient balance and body weight control. Int J Obes Relat Metab Disord, 1995, 19: 79-86.Tremblay A, Buemann B. Exercise-training, macronutrient balance and body weight control. Int J Obes Relat Metab Disord, 1995, 19: 79-86.Yanovski SZ, Yanovski JA. Obesity. N Engl J Med, 2002, 346: 591-602.Yanovski SZ, Yanovski JA. Obesity. N Engl J Med, 2002, 346: 591-602.Wadden TA, Foster GD. Behaviorial treatment of obesity. Med Clin North Am, 2000, 85: 441-61.Wadden TA, Foster GD. Behaviorial treatment of obesity. Med Clin North Am, 2000, 85: 441-61.Wirth A. reduction of body weight and co-morbidities by orlistat: The XXL- primary Health Care Trial. Diabetes, Obesity and Metabolizm, 2005, 7: 21-7.Wirth A. reduction of body weight and co-morbidities by orlistat: The XXL- primary Health Care Trial. Diabetes, Obesity and Metabolizm, 2005, 7: 21-7.Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res., 1998, 6: 97-106.Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res., 1998, 6: 97-106.Zanella MT, Uehara MH, Ribeiro AB. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol, 2006, 50(2): 368-76.Zanella MT, Uehara MH, Ribeiro AB. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol, 2006, 50(2): 368-76.Zhou Y-H, Ma X-Q, Wu C et al. Effect of AntiObesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2012, 7(6): e39062. doi:10.1371/journal.pone.0039062.Zhou Y-H, Ma X-Q, Wu C et al. Effect of AntiObesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2012, 7(6): e39062. doi:10.1371/journal.pone.0039062.

The authors declare that there are no conflicts of interest present.